Kuur Therapeutics
London
About Kuur Therapeutics
Kuur Therapeutics is committed to transforming the lives of patients with cancer and is leading the development of off-the-shelf engineered CAR-NKT cell therapies. Our approach combines the highly differentiated, natural biology of a specific subset of cytotoxic T cells, called natural killer T cells (NKT cells) and innovative CAR construct engineering. In combination, this delivers a very compelling and unique platform, that we believe has the potential to produce many future therapies targeting both hematological and solid tumors.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $191.8M
- Funding stage: M&A
- Last round: Secondary Market (Jan 2021)
- Website: kuurtx.com
- Phone: 44 20 7554 4070
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/kuur-therapeutics-92468 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.